Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMethimazole
Identification
- Name
- Methimazole
- Accession Number
- DB00763 (APRD00002)
- Type
- Small Molecule
- Groups
- Approved
- Description
A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme. [PubChem]
- Structure
Structure for DB00763 (Methimazole)
- Synonyms
- 1-METHYL-1,3-dihydro-2H-imidazole-2-thione
- 1-Methylimidazole-2(3H)-thione
- Danantizol
- Favistan
- Mercazolyl
- Methimazole
- Strumazol
- Thacapzol
- Thiamazol
- Thiamazole
- Thiamazolum
- Tiamazol
- USAF el-30
- External IDs
- NSC 38608 / UNII-554Z48XN5E
- Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Tapazole Tablet 10 mg Oral Paladin Labs Inc 2008-01-07 Not applicable Canada 
Tapazole Tablet 20 mg Oral Paladin Labs Inc Not applicable Not applicable Canada Tapazole 5mg Tablet Tablet 5 mg Oral Paladin Labs Inc 1951-12-31 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-methimazole Tablet 5 mg Oral Apotex Corporation 2005-03-18 Not applicable Canada Dom-methimazole Tablet 5 mg Oral Dominion Pharmacal Not applicable Not applicable Canada Methimazole Tablet 5 mg/1 Oral Golden State Medical Supply 2013-01-08 Not applicable US 
Methimazole Tablet 10 mg/1 Oral Preferreed Pharmaceuticals Inc. 2014-02-27 Not applicable US Methimazole Tablet 5 mg/1 Oral Heritage 2012-01-16 Not applicable US Methimazole Tablet 5 mg/1 Oral Eon Labs, Inc. 2001-03-27 Not applicable US Methimazole Tablet 10 mg/1 Oral Dispensing Solutions, Inc. 2012-01-16 Not applicable US 
Methimazole Tablet 10 mg/1 Oral Par Pharmaceutical 2000-03-29 Not applicable US Methimazole Tablet 10 mg/1 Oral Boca Pharmacal, Inc. 2012-03-07 2017-02-28 US Methimazole Tablet 10 mg/1 Oral Eci Pharmaceuticals Llc 2016-07-01 Not applicable US - International/Other Brands
- Danantizol (Gador S.A.) / Favistan (Temmler) / Metizol (ICN) / Strumazol (Organon) / Strumazole / Tapazole / Thacapzol (Recip) / Thycapzol (Sandoz) / Thyrozol (Merck) / Tirozol (Merck)
- Categories
- Antithyroid Agents
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (weak)
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Imidazoles
- Immunosuppressive Agents
- Myelosuppressive Agents
- Sulfhydryl Compounds
- Sulfur Compounds
- Sulfur-Containing Imidazole Derivatives
- Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins
- Thyroid Hormone Synthesis Inhibitor
- Thyroid Therapy
- UNII
- 554Z48XN5E
- CAS number
- 60-56-0
- Weight
- Average: 114.169
Monoisotopic: 114.025168892 - Chemical Formula
- C4H6N2S
- InChI Key
- PMRYVIKBURPHAH-UHFFFAOYSA-N
- InChI
- InChI=1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)
- IUPAC Name
- 1-methyl-2,3-dihydro-1H-imidazole-2-thione
- SMILES
- CN1C=CNC1=S
Pharmacology
- Indication
For the treatment of hyperthyroidism, goiter, Graves disease and psoriasis.
- Associated Conditions
- Pharmacodynamics
Used in the treatment of hyperthyroidism or an overactive thyroid gland, methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. It may also be used to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy.
- Mechanism of action
Methimazole binds to thyroid peroxidase and thereby inhibits the conversion of iodide to iodine. Thyroid peroxidase normally converts iodide to iodine (via hydrogen peroxide as a cofactor) and also catalyzes the incorporation of the resulting iodide molecule onto both the 3 and/or 5 positions of the phenol rings of tyrosines found in thyroglobulin. Thyroglobulin is degraded to produce thyroxine (T4) and tri-iodothyronine (T3), which are the main hormones produced by the thyroid gland. So methimazole effectively inhibits the production of new thyroid hormones.
Target Actions Organism AThyroid peroxidase inhibitorHuman - Absorption
Rapid with an oral bioavailability of 93%.
- Volume of distribution
- Not Available
- Protein binding
None or minimal
- Metabolism
Primarily hepatic. Metabolized rapidly, requiring frequent administration.
- Route of elimination
Methimazole is excreted in the urine.
- Half life
5-6 hours
- Clearance
- Not Available
- Toxicity
Oral LD50 in rats is 2250 mg/kg. Symptoms of overdose include nausea, vomiting, epigastric distress, headache, fever, joint pain, pruritus, and edema. Aplastic anemia (pancy-topenia) or agranulocytosis may be manifested in hours to days. Less frequent events are hepatitis, nephrotic syndrome, exfoliative dermatitis, neuropathies, and CNS stimulation or depression.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Acenocoumarol Methimazole may decrease the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with Methimazole. Approved Acetyldigoxin The serum concentration of Acetyldigoxin can be increased when it is combined with Methimazole. Experimental Ambroxol acefyllinate The serum concentration of Ambroxol acefyllinate can be increased when it is combined with Methimazole. Experimental, Investigational Aminophylline The serum concentration of Aminophylline can be increased when it is combined with Methimazole. Approved Artesunate The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Methimazole resulting in a loss in efficacy. Approved, Investigational Asunaprevir The serum concentration of Asunaprevir can be increased when it is combined with Methimazole. Approved, Investigational, Withdrawn Atorvastatin The risk or severity of adverse effects can be increased when Methimazole is combined with Atorvastatin. Approved Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Methimazole. Approved Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Methimazole. Approved, Investigational Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Methimazole. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Methimazole. Approved, Withdrawn Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Methimazole. Approved, Investigational Clorindione Methimazole may decrease the anticoagulant activities of Clorindione. Experimental Clozapine The risk or severity of adverse effects can be increased when Methimazole is combined with Clozapine. Approved Cymarin The serum concentration of Cymarin can be increased when it is combined with Methimazole. Experimental Deslanoside The serum concentration of Deslanoside can be increased when it is combined with Methimazole. Approved Dicoumarol Methimazole may decrease the anticoagulant activities of Dicoumarol. Approved Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Methimazole. Approved, Investigational Digoxin The serum concentration of Digoxin can be increased when it is combined with Methimazole. Approved Digoxin Immune Fab (Ovine) The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Methimazole. Approved Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Methimazole. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Methimazole. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Methimazole. Experimental Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methimazole. Approved, Investigational Diphenadione Methimazole may decrease the anticoagulant activities of Diphenadione. Experimental Dyphylline The serum concentration of Dyphylline can be increased when it is combined with Methimazole. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Methimazole. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Methimazole. Approved Ethyl biscoumacetate Methimazole may decrease the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methimazole. Approved Fluindione Methimazole may decrease the anticoagulant activities of Fluindione. Approved, Investigational Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Methimazole. Approved Gitoformate The serum concentration of Gitoformate can be increased when it is combined with Methimazole. Experimental Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Methimazole. Approved Iodide I-131 The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Methimazole. Approved, Investigational Lanatoside C The serum concentration of Lanatoside C can be increased when it is combined with Methimazole. Experimental Lipegfilgrastim Methimazole may increase the myelosuppressive activities of Lipegfilgrastim. Approved, Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Methimazole. Approved, Investigational Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Methimazole. Approved, Investigational Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Methimazole. Illicit, Investigational, Withdrawn Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Methimazole. Approved, Investigational, Withdrawn Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Methimazole. Experimental Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Methimazole. Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Methimazole. Approved Metildigoxin The serum concentration of Metildigoxin can be increased when it is combined with Methimazole. Experimental Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Methimazole. Approved, Investigational Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Methimazole. Experimental Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Methimazole. Approved, Investigational Oleandrin The serum concentration of Oleandrin can be increased when it is combined with Methimazole. Experimental, Investigational Ouabain The serum concentration of Ouabain can be increased when it is combined with Methimazole. Approved Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Methimazole. Approved, Investigational, Vet Approved, Withdrawn Peruvoside The serum concentration of Peruvoside can be increased when it is combined with Methimazole. Experimental Phenindione Methimazole may decrease the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Methimazole may decrease the anticoagulant activities of Phenprocoumon. Approved, Investigational Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Methimazole. Approved Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Methimazole. Approved, Investigational Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Methimazole. Approved Prednisolone The serum concentration of Prednisolone can be decreased when it is combined with Methimazole. Approved, Vet Approved Proscillaridin The serum concentration of Proscillaridin can be increased when it is combined with Methimazole. Experimental Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Methimazole. Approved Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Methimazole. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Methimazole. Approved Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Methimazole. Experimental Theophylline The serum concentration of Theophylline can be increased when it is combined with Methimazole. Approved Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Methimazole. Approved, Withdrawn Tioclomarol Methimazole may decrease the anticoagulant activities of Tioclomarol. Experimental Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Methimazole. Approved, Investigational Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Methimazole. Approved Warfarin Methimazole may decrease the anticoagulant activities of Warfarin. Approved - Food Interactions
- Always take at the same moment in regard to meals, food may affect absorption unpredictably.
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014901
- KEGG Drug
- D00401
- KEGG Compound
- C07190
- PubChem Compound
- 1349907
- PubChem Substance
- 46506536
- ChemSpider
- 1131173
- BindingDB
- 50241361
- ChEBI
- 50673
- ChEMBL
- CHEMBL1515
- Therapeutic Targets Database
- DNC001429
- PharmGKB
- PA450422
- HET
- MMZ
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Methimazole
- ATC Codes
- H03BB02 — Thiamazole
- H03BB — Sulfur-containing imidazole derivatives
- H03B — ANTITHYROID PREPARATIONS
- H03 — THYROID THERAPY
- H — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
- AHFS Codes
- 68:36.08 — Antithyroid Agents
- PDB Entries
- 2gvc / 4ig5 / 5ff1 / 5gsn
- MSDS
- Download (75.8 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1, 2 Completed Treatment Graves´ Disease / Thyroid Associated Ophthalmopathy 1 2 Completed Treatment Dermatomyositis / Polymyositis 1 2 Terminated Supportive Care Glioblastoma Multiforme (GBM) 1 3 Recruiting Treatment Graves Diseases / Graves Ophthalmopathy / Graves' Ophthalmopathy Worsened 1 4 Completed Prevention Graves´ Disease 1 4 Completed Treatment Graves Diseases / Toxic Nodular Goitre 1 4 Completed Treatment Graves' Disease / Toxic Nodular Goitre 1 4 Unknown Status Diagnostic Healthy Volunteers 1 Not Available Completed Not Available Graves Diseases 1 Not Available Completed Treatment Graves Diseases 1 Not Available Completed Treatment Graves' Disease 1 Not Available Recruiting Not Available Gut Microbiota 1 Not Available Terminated Treatment Graves Ophthalmopathy 1
Pharmacoeconomics
- Manufacturers
- Actavis totowa llc
- Caraco pharmaceutical laboratories ltd
- Cedar pharmaceuticals llc
- Mylan pharmaceuticals inc
- Sandoz inc
- King pharmaceuticals inc
- King pharmaceuticals research and development inc sub king pharmaceuticals inc
- Packagers
- AAIPharma Inc.
- Actavis Group
- Amerisource Health Services Corp.
- Caraco Pharmaceutical Labs
- Cedar Pharmaceuticals LLC
- Centrix Pharmaceuticals
- Dispensing Solutions
- Eon Labs
- Heartland Repack Services LLC
- Kaiser Foundation Hospital
- King Pharmaceuticals Inc.
- Medisca Inc.
- Mikart Inc.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Nucare Pharmaceuticals Inc.
- Par Pharmaceuticals
- Philopharm GmbH
- Physicians Total Care Inc.
- Remedy Repack
- Resource Optimization and Innovation LLC
- Southwood Pharmaceuticals
- United Research Laboratories Inc.
- Vangard Labs Inc.
- Dosage forms
Form Route Strength Tablet Oral 10 mg/1 Tablet Oral 5 mg/1 Tablet Oral 10 mg Tablet Oral 20 mg Tablet Oral 5 mg - Prices
Unit description Cost Unit Methimazole powder 9.49USD g Methimazole 20 mg tablet 1.9USD tablet Tapazole 10 mg tablet 1.45USD tablet Northyx 20 mg tablet 0.94USD tablet Northyx 15 mg tablet 0.82USD tablet Methimazole 10 mg tablet 0.78USD tablet Tapazole 5 mg tablet 0.66USD tablet Northyx 10 mg tablet 0.47USD tablet Methimazole 5 mg tablet 0.45USD tablet Northyx 5 mg tablet 0.29USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 146 °C PhysProp boiling point (°C) 280 °C PhysProp water solubility 275 g/L Not Available logP -0.34 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 11.3 mg/mL ALOGPS logP -0.38 ALOGPS logP 0.75 ChemAxon logS -1 ALOGPS pKa (Strongest Acidic) 10.41 ChemAxon pKa (Strongest Basic) -3 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 0 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 15.27 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 33.23 m3·mol-1 ChemAxon Polarizability 11.64 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9156 Blood Brain Barrier + 0.9731 Caco-2 permeable + 0.6156 P-glycoprotein substrate Non-substrate 0.8213 P-glycoprotein inhibitor I Non-inhibitor 0.7552 P-glycoprotein inhibitor II Non-inhibitor 0.944 Renal organic cation transporter Non-inhibitor 0.7662 CYP450 2C9 substrate Non-substrate 0.7919 CYP450 2D6 substrate Non-substrate 0.8985 CYP450 3A4 substrate Non-substrate 0.7849 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.9232 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.8309 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.7105 Ames test Non AMES toxic 0.8582 Carcinogenicity Non-carcinogens 0.9348 Biodegradation Not ready biodegradable 0.9815 Rat acute toxicity 1.8215 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9401 hERG inhibition (predictor II) Non-inhibitor 0.8416
Spectra
- Mass Spec (NIST)
- Download (8.12 KB)
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as imidazolethiones. These are aromatic compounds containing an imidazole ring which bears a thioketone group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azolines
- Sub Class
- Imidazolines
- Direct Parent
- Imidazolethiones
- Alternative Parents
- N-substituted imidazoles / Heteroaromatic compounds / Thioureas / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
- Substituents
- N-substituted imidazole / Imidazole-2-thione / Heteroaromatic compound / Imidazole / Azole / Thiourea / Azacycle / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- imidazoles, thioureas (CHEBI:50673) / a small molecule (CPD-11282)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Peroxidase activity
- Specific Function
- Iodination and coupling of the hormonogenic tyrosines in thyroglobulin to yield the thyroid hormones T(3) and T(4).
- Gene Name
- TPO
- Uniprot ID
- P07202
- Uniprot Name
- Thyroid peroxidase
- Molecular Weight
- 102961.63 Da
References
- Sugawara M, Sugawara Y, Wen K: Methimazole and propylthiouracil increase cellular thyroid peroxidase activity and thyroid peroxidase mRNA in cultured porcine thyroid follicles. Thyroid. 1999 May;9(5):513-8. [PubMed:10365684]
- Manzon RG, Holmes JA, Youson JH: Variable effects of goitrogens in inducing precocious metamorphosis in sea lampreys (Petromyzon marinus). J Exp Zool. 2001 Apr 15;289(5):290-303. [PubMed:11241400]
- Ferreira AC, de Carvalho Cardoso L, Rosenthal D, de Carvalho DP: Thyroid Ca2+/NADPH-dependent H2O2 generation is partially inhibited by propylthiouracil and methimazole. Eur J Biochem. 2003 Jun;270(11):2363-8. [PubMed:12755690]
- Magnusson RP, Yu B, Brennan V: Effect of serum thyrotropin levels on the concentration of messenger RNA for thyroid peroxidase in the rat. Acta Endocrinol (Copenh). 1992 May;126(5):460-6. [PubMed:1320313]
- Chiovato L, Pinchera A: The microsomal/peroxidase antigen: modulation of its expression in thyroid cells. Autoimmunity. 1991;10(4):319-31. [PubMed:1663395]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
- Gene Name
- CYP2A6
- Uniprot ID
- P11509
- Uniprot Name
- Cytochrome P450 2A6
- Molecular Weight
- 56501.005 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2B6
- Uniprot ID
- P20813
- Uniprot Name
- Cytochrome P450 2B6
- Molecular Weight
- 56277.81 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
- Gene Name
- CYP2E1
- Uniprot ID
- P05181
- Uniprot Name
- Cytochrome P450 2E1
- Molecular Weight
- 56848.42 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Drug created on June 13, 2005 07:24 / Updated on July 18, 2018 17:36